Skip to main content

Advertisement

SpringerLink
Log in

Defining co-related parameters between ‘metabolic’ flare and ‘clinical’, ‘biochemical’, and ‘osteoblastic’ flare and establishing guidelines for assessing response to treatment in cancer

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35 13:1773–82.

    Article  PubMed  CAS  Google Scholar 

  2. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46 6:983–95.

    PubMed  CAS  Google Scholar 

  3. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56–68.

    PubMed  Google Scholar 

  4. Basu S, Nair N. Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours? Nucl Med Commun 2006;27 5:413–6.

    Article  PubMed  Google Scholar 

  5. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26 1:51–6.

    Article  PubMed  CAS  Google Scholar 

  6. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19 11:2797–803.

    PubMed  CAS  Google Scholar 

  7. Biersack HJ, Bender H, Palmedo H. FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S112–7.

    Article  PubMed  Google Scholar 

  8. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systematic therapy for bone metastases [abstract]. J Nucl Med 1988;29:1354–9.

    PubMed  CAS  Google Scholar 

  9. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995;13 5:1123–8.

    PubMed  CAS  Google Scholar 

  10. Tarle M, Kovacic K, Strelkov-Alfirevic A. Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monitoring patients with disseminated cancer of the prostate. Prostate 1989;15 3:211–9.

    Article  PubMed  CAS  Google Scholar 

  11. Koizumi M, Matsumoto S, Takahashi S, Yamashita T, Ogata E. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 1999;24 1:15–20.

    Article  PubMed  CAS  Google Scholar 

  12. Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol 2006;186 6:1783–6.

    Article  PubMed  Google Scholar 

  13. Shimizu N, Masud H, Yamanaka H, Oriuchi N, Inoue T, Endo K. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy. J Urol 1999;161:608–9.

    Article  PubMed  CAS  Google Scholar 

  14. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413–6.

    Article  PubMed  CAS  Google Scholar 

  15. Kahan A, Delreiu F, Amor B, Chiche R, Steg A. Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 1984;1:971–2.

    Article  PubMed  CAS  Google Scholar 

  16. Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. BJU Int 2000;85:690–5.

    Article  PubMed  CAS  Google Scholar 

  17. Bubley GJ. Is the flare clinically significant? Urology 2001;58 Supplement 2A:5–9.

    Article  PubMed  CAS  Google Scholar 

  18. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flares with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990;144 6:1479–80.

    PubMed  CAS  Google Scholar 

  19. Plotkin D, Lechner JJ, Jung WE, Rosen PJ. Tamoxifen flare in advanced breast cancer. JAMA 1978;240:2644–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This work was supported in part by the International Union against Cancer (UICC), Geneva, Switzerland, under the ACSBI fellowship.

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, 19104, USA

    Sandip Basu & Abass Alavi

Authors
  1. Sandip Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abass Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abass Alavi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basu, S., Alavi, A. Defining co-related parameters between ‘metabolic’ flare and ‘clinical’, ‘biochemical’, and ‘osteoblastic’ flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging 34, 441–443 (2007). https://doi.org/10.1007/s00259-006-0264-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0264-6

Search

Navigation